Research Article Details

Article ID: A28173
PMID: 16226488
Source: Hepatol Res
Title: Epidemiological aspects of obesity and NASH/NAFLD in Japan.
Abstract: Although the characteristics of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) have become well recognized, mainly in the clinical and pathological fields, epidemiological findings, including magnitude of the disease in a population (prevalence, outcomes, and mortality) and risk factors (relative risk and population attributable risk) are scarce in the Asia-Oceania region. Obesity is known to be one of the most important risk factors for NASH/NAFLD, and observed increases in NASH/NAFLD in selected areas or settings may be linked to the increase in overweight and obesity in Japanese adults in the last few decades. Obesity could be a major key to explaining NASH/NAFLD, because of the complex causal web that includes obesity, insulin resistance, dyslipidemia, high blood pressure, etc. In this paper epidemiological data on overweight and obesity were summarized as underlying factors for NAFLD with special reference to yearly trends and regional differences in the prevalence of obesity and overweight in Japanese adults using large-scale representative samples from the National Nutrition Surveys. Unfortunately, as very few published reports on population-based epidemiological data for NAFLD are currently available, we referred to selected data obtained from field settings to estimate the prevalence of NAFLD in the general population and its risk factors or associated factors. It is important to understand NASH/NAFLD as a common "burden of disease" in the populations if effective strategies to control these disorders are to be devised as part of public health initiatives.
DOI: 10.1016/j.hepres.2005.09.008

Strategy ID Therapy Strategy Synonyms Therapy Targets Therapy Drugs
S01 Improve insulin resistance insulin sensitizer; insulin resistance; glucose tolerance Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide Details

Target ID Target Name GENE Action Class UniProtKB ID Entry Name

Diseases ID DO ID Disease Name Definition Class
I13 3146 Lipid metabolism disorder An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism disease of metabolism/ inherited metabolic disorder Details
I05 9352 Type 2 diabetes mellitus A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus Details
I14 9970 Obesity An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition Details

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D328 Serine Chemical drug DB00133 SRR Improve insulin resistance Under clinical trials Details
D316 S-adenosyl-L-methionine Chemical drug DB00118 GNMT cofactor Antiviral Under clinical trials Details
D182 Insulin Biological drug DB00030 INSR agonist; CPE modulator&product of -- Under clinical trials Details